Medicare Puts 505(b)(2) Changes On Hold
Walks Back Proposed Payment Policy For 505(b)(2) Physician Administered Drugs
Executive Summary
CMS acknowledges stakeholders may need more details about the plan before it is finalized and a delay will give the agency more time to ‘consider the issue.’